Maravai is a holding company. Through its subsidiaries, Co. operates as a life sciences company that provides products to enable the development of drug, therapies, diagnostics, vaccines, and support research on human diseases. Co. operates in two segments: Nucleic Acid Production, which includes messenger ribonucleic acid, long and short oligonucleotides, its CleanCap® capping technology and oligonucleotide building blocks; and Biologics Safety Testing, which sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The MRVI stock yearly return is shown above.
The yearly return on the MRVI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MRVI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|